Keywords
PolypharmacyMetabolic syndromeMedicineIntensive care medicineDrugDiseaseDiabetes mellitusPharmacotherapyObesityBioinformaticsPharmacologyInternal medicineEndocrinologyBiology
Affiliated Institutions
Related Publications
The Metabolic Syndrome: Time for a Critical Appraisal
The term “metabolic syndrome” refers to a clustering of specific cardiovascular disease (CVD) risk factors whose underlying pathophysiology is thought to be related to insulin r...
Metabolic Syndrome: Updates on Pathophysiology and Management in 2021
Metabolic syndrome (MetS) forms a cluster of metabolic dysregulations including insulin resistance, atherogenic dyslipidemia, central obesity, and hypertension. The pathogenesis...
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
OBJECTIVE—To estimate the prevalence of and the cardiovascular risk associated with the metabolic syndrome using the new definition proposed by the World Health Organization (WH...
The Metabolic Syndrome and Total and Cardiovascular Disease Mortality in Middle-aged Men
Cardiovascular disease and all-cause mortality are increased in men with the metabolic syndrome, even in the absence of baseline CVD and diabetes. Early identification, treatmen...
Publication Info
- Year
- 2006
- Type
- review
- Volume
- 5
- Issue
- 4
- Pages
- 295-309
- Citations
- 283
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
283
OpenAlex
Cite This
Scott M. Grundy
(2006).
Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy.
Nature Reviews Drug Discovery
, 5
(4)
, 295-309.
https://doi.org/10.1038/nrd2005
Identifiers
- DOI
- 10.1038/nrd2005